88 results on '"Crazzolara R"'
Search Results
2. Combination therapy of omega-3 fatty acids and acipimox for children with hypertriglyceridemia and acute lymphoblastic leukemia
- Author
-
Salvador, C., Entenmann, A., Salvador, R., Niederwanger, A., Crazzolara, R., and Kropshofer, G.
- Published
- 2018
- Full Text
- View/download PDF
3. Morphologische Veränderungen des Knochengewebes bei Osteopetrose
- Author
-
Zustin, J., Amling, M., Crazzolara, R., Butscheidt, S., Schulz, A., and Oheim, R.
- Published
- 2018
- Full Text
- View/download PDF
4. P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
- Author
-
Novak, W., primary, Annamária, C., additional, Crazzolara, R., additional, Neil, J., additional, Pirolt, K., additional, Dworzak, M., additional, and Kager, L., additional
- Published
- 2022
- Full Text
- View/download PDF
5. TRANSPLANT ASSOCIATED MICROANGIOPATHY (TMA) COMPLICATED BY TRANSFUSION RELATED ACUTE LUNG INJURY (TRALI) IN A TWO YEAR OLD BOY: PH-AB111
- Author
-
Salvador, C., Crazzolara, R., Meister, B., Hofer, J., Klingkowski, U., and Kropshofer, G.
- Published
- 2014
6. Morphologische Veränderungen des Knochengewebes bei Osteopetrose
- Author
-
Zustin, J., primary, Amling, M., additional, Crazzolara, R., additional, Butscheidt, S., additional, Schulz, A., additional, and Oheim, R., additional
- Published
- 2017
- Full Text
- View/download PDF
7. Monitoring of bone marrow minimal residual disease combined with genetic analysis identifies different risk groups in stage M neuroblastoma patients
- Author
-
Riegler, S, additional, Ambros, IM, additional, Pötschger, U, additional, Mann, G, additional, Ziegler, A, additional, Modritz, D, additional, Crazzolara, R, additional, Ussowicz, M, additional, Benesch, M, additional, Ebetsberger-Dachs, G, additional, Schleiermacher, G, additional, Chan, GC, additional, Jones, N, additional, Yaniv, I, additional, Balwierz, W, additional, Holter, W, additional, Ladenstein, R, additional, and Ambros, PF, additional
- Published
- 2017
- Full Text
- View/download PDF
8. Mechanisms of brain injury in infantile child abuse
- Author
-
Heinz-Erian, P, Crazzolara, R, and Sass, J O
- Subjects
Child abuse -- Physiological aspects ,Shaken baby syndrome -- Physiological aspects ,Brain -- Injuries - Published
- 2001
9. Management of chronic immune thrombocytopenia in children and adolescents: lessons from an Austrian national cross-sectional study of 81 patients
- Author
-
Sipurzynski, J., primary, Fahrner, B., additional, Kerbl, R., additional, Crazzolara, R., additional, Jones, N., additional, Ebetsberger, G., additional, Jauk, B., additional, Strenger, V., additional, Wohlmuther, B., additional, Schwinger, W., additional, Lackner, H., additional, Urban, C., additional, Holter, W., additional, Minkov, M., additional, Kager, L., additional, Benesch, M., additional, and Seidel, M.G., additional
- Published
- 2016
- Full Text
- View/download PDF
10. 4101 Mammalian target of rapamycin (mTOR) inhibition in acute lymphoblastic leukemia: a promising therapeutic option
- Author
-
Crazzolara, R., primary, Cisterne, A., additional, Thien, M., additional, Hewson, J., additional, Baraz, R., additional, Bradstock, K., additional, and Bendall, L., additional
- Published
- 2009
- Full Text
- View/download PDF
11. Emerging Treatments in Acute Lymphoblastic Leukemia
- Author
-
Crazzolara, R., primary and Bendall, L., additional
- Published
- 2009
- Full Text
- View/download PDF
12. Limbic encephalitis with voltage gated potassium channel antibodies in a child
- Author
-
Haberlandt, E, primary, Bien, CG, additional, Reiter, A, additional, Simma, B, additional, Crazzolara, R, additional, Scholl-Buergi, S, additional, Rostasy, K, additional, and Karall, D, additional
- Published
- 2008
- Full Text
- View/download PDF
13. Mechanisms of brain injury in infantile child abuse
- Author
-
Sass, JO, primary, Crazzolara, R, additional, and Heinz-Erian, P, additional
- Published
- 2001
- Full Text
- View/download PDF
14. Brief report: teratocarcinosarcoma of the oral cavity.
- Author
-
Crazzolara R, Puelacher W, Ninkovic M, Zelger B, Buchberger W, Meister B, Zimmerhackl LB, and Klein-Franke A
- Published
- 2004
- Full Text
- View/download PDF
15. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.
- Author
-
Corbacioglu S, Lode H, Ellinger S, Zeman F, Suttorp M, Escherich G, Bochennek K, Gruhn B, Lang P, Rohde M, Debatin KM, Steinbach D, Beilken A, Ladenstein R, Spachtholz R, Heiss P, Hellwig D, Tröger A, Koller M, Menhart K, Riemenschneider MJ, Zoubaa S, Kietz S, Jakob M, Sommer G, Heise T, Hundsdörfer P, Kühnle I, Dilloo D, Schönberger S, Schwabe G, von Luettichau I, Graf N, Schlegel PG, Frühwald M, Jorch N, Paulussen M, Schneider DT, Metzler M, Leipold A, Nathrath M, Imschweiler T, Christiansen H, Schmid I, Crazzolara R, Niktoreh N, Cario G, Faber J, Demmert M, Babor F, Fröhlich B, Bielack S, Bernig T, Greil J, Eggert A, Simon T, and Foell J
- Subjects
- Humans, Male, Female, Child, Preschool, Child, Adolescent, Infant, Adult, Young Adult, Germany, Drug Resistance, Neoplasm, Progression-Free Survival, Temozolomide administration & dosage, Temozolomide therapeutic use, Irinotecan administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Neuroblastoma drug therapy, Neuroblastoma mortality, Neuroblastoma pathology, Neuroblastoma genetics, Dasatinib administration & dosage, Dasatinib therapeutic use, Dasatinib adverse effects, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Sirolimus administration & dosage, Sirolimus therapeutic use
- Abstract
Background: Neuroblastoma is the most common extracranial solid tumour in children. Relapsed or refractory neuroblastoma is associated with a poor outcome. We assessed the combination of irinotecan-temozolomide and dasatinib-rapamycin (RIST) in patients with relapsed or refractory neuroblastoma., Methods: The multicentre, open-label, randomised, controlled, phase 2, RIST-rNB-2011 trial recruited from 40 paediatric oncology centres in Germany and Austria. Patients aged 1-25 years with high-risk relapsed (defined as recurrence of all stage IV and MYCN amplification stages, after response to treatment) or refractory (progressive disease during primary treatment) neuroblastoma, with Lansky and Karnofsky performance status at least 50%, were assigned (1:1) to RIST (RIST group) or irinotecan-temozolomide (control group) by block randomisation, stratified by MYCN status. We compared RIST (oral rapamycin [loading 3 mg/m
2 on day 1, maintenance 1 mg/m2 on days 2-4] and oral dasatinib [2 mg/kg per day] for 4 days with 3 days off, followed by intravenous irinotecan [50 mg/m2 per day] and oral temozolomide [150 mg/m2 per day] for 5 days with 2 days off; one course each of rapamycin-dasatinib and irinotecan-temozolomide for four cycles over 8 weeks, then two courses of rapamycin-dasatinib followed by one course of irinotecan-temozolomide for 12 weeks) with irinotecan-temozolomide alone (with identical dosing as experimental group). The primary endpoint of progression-free survival was analysed in all eligible patients who received at least one course of therapy. The safety population consisted of all patients who received at least one course of therapy and had at least one post-baseline safety assessment. This trial is registered at ClinicalTrials.gov, NCT01467986, and is closed to accrual., Findings: Between Aug 26, 2013, and Sept 21, 2020, 129 patients were randomly assigned to the RIST group (n=63) or control group (n=66). Median age was 5·4 years (IQR 3·7-8·1). 124 patients (78 [63%] male and 46 [37%] female) were included in the efficacy analysis. At a median follow-up of 72 months (IQR 31-88), the median progression-free survival was 11 months (95% CI 7-17) in the RIST group and 5 months (2-8) in the control group (hazard ratio 0·62, one-sided 90% CI 0·81; p=0·019). Median progression-free survival in patients with amplified MYCN (n=48) was 6 months (95% CI 4-24) in the RIST group versus 2 months (2-5) in the control group (HR 0·45 [95% CI 0·24-0·84], p=0·012); median progression-free survival in patients without amplified MYCN (n=76) was 14 months (95% CI 9-7) in the RIST group versus 8 months (4-15) in the control group (HR 0·84 [95% CI 0·51-1·38], p=0·49). The most common grade 3 or worse adverse events were neutropenia (54 [81%] of 67 patients given RIST vs 49 [82%] of 60 patients given control), thrombocytopenia (45 [67%] vs 41 [68%]), and anaemia (39 [58%] vs 38 [63%]). Nine serious treatment-related adverse events were reported (five patients given control and four patients given RIST). There were no treatment-related deaths in the control group and one in the RIST group (multiorgan failure)., Interpretation: RIST-rNB-2011 demonstrated that targeting of MYCN-amplified relapsed or refractory neuroblastoma with a pathway-directed metronomic combination of a multkinase inhibitor and an mTOR inhibitor can improve progression-free survival and overall survival. This exclusive efficacy in MYCN-amplified, relapsed neuroblastoma warrants further investigation in the first-line setting., Funding: Deutsche Krebshilfe., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.)- Published
- 2024
- Full Text
- View/download PDF
16. Prophylaxis with enoxaparin and antithrombin III in drug-induced coagulation alterations in childhood leukemia: a retrospective experience of 20 years.
- Author
-
Salvador C, Salvador R, Kropshofer G, Meister B, Rock M, Obexer P, Hetzer B, Rabensteiner E, and Crazzolara R
- Abstract
Background: Thromboembolic complications are well known in the treatment of childhood acute lymphoblastic leukemia. Over the years it has not been possible to reach a consensus on a possible prophylaxis of thromboembolic events during intensive therapy. Only the administration of enoxaparin was able to achieve evidence in the literature to date., Methods: In this retrospective study, 173 childhood leukemia patients were treated over 20 years with a thromboembolic prophylaxis including enoxaparin and AT III during induction therapy with L-asparaginase and cortisone., Results: We here report the effectiveness of administration of enoxaparin and AT III in childhood leukemia, showing a strikingly low prevalence of deep vein thrombosis (2.9%). Especially in adolescent patients, a particularly great need for AT III was demonstrated., Conclusions: We recommend thromboembolic prophylaxis with enoxaparin and AT III substitution during induction/reinduction therapy with L-asparaginase and glucocorticosteroids, especially from adolescence onwards., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. Integration of Daily Patient-Reported Outcome Measures in Pediatric Stem Cell Transplantation.
- Author
-
Hetzer B, Meryk A, Kropshofer G, Salvador C, Riedl D, Lehmann J, Rumpold G, Haid A, Schneeberger-Carta V, Holzner B, and Crazzolara R
- Subjects
- Humans, Child, Infant, Child, Preschool, Adolescent, Transplantation, Homologous, Retrospective Studies, Stem Cell Transplantation, Nausea, Quality of Life, Hematopoietic Stem Cell Transplantation
- Abstract
Patients' reports of their health status are increasingly used in hematopoietic stem cell transplantation (SCT) to better understand the negative impact on symptom burden and quality of life. Little is known regarding the implementation in routine clinical care, particularly how it can be used to improve supportive care. We sought to the evaluate feasibility of capturing daily patient-reported outcomes (PROs) in the acute phase of SCT to measure physical and psychosocial symptom burden. In this single-center prospective observational study, we assessed daily PRO from conditioning to neutrophil engraftment in children (age 1 to 18 year) who underwent allogeneic or autologous SCT for malignant and nonmalignant disease. The most common acute adverse effects of chemotherapy (pain, nausea, loss of appetite, sleep disturbance, and physical performance impairment) were reported daily via ePROtect, a web-based program designed to integrate health responses. From February 2021 to March 2023, 20 children undergoing allogeneic (allo-) SCT (n = 11) or autologous (auto-) SCT (n = 9) and their proxies consented to participation, all of whom were included in this analysis. A total of 359 PRO questionnaires were completed, corresponding to a median daily completion rate of 72.7% (interquartile range, 60.4% to 83.6%). After conditioning, pain perception anticipated the rise of infectious parameters and the development of mucositis, thus initiating supportive treatment. Patients reported the strongest symptom burden at a median of 8.5 days post-transplantation. At 4 weeks post-transplantation, baseline values were restored for all symptoms. There were no significant differences between auto-SCT and allo-SCT, except for nausea and loss of appetite after administration of antithymocyte globulin in allo-SCT. This study empirically documents the daily health status of children undergoing SCT and proposes an attractive modus operandi on how continuous feedback on health-related symptoms can be integrated into daily clinical practice., (Copyright © 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
18. Distinct clinical phenotypes in paediatric cancer patients with sepsis are associated with different outcomes-an international multicentre retrospective study.
- Author
-
Wösten-van Asperen RM, la Roi-Teeuw HM, van Amstel RB, Bos LD, Tissing WJ, Jordan I, Dohna-Schwake C, Bottari G, Pappachan J, Crazzolara R, Comoretto RI, Mizia-Malarz A, Moscatelli A, Sánchez-Martín M, Willems J, Rogerson CM, Bennett TD, Luo Y, Atreya MR, Faustino EVS, Geva A, Weiss SL, Schlapbach LJ, and Sanchez-Pinto LN
- Abstract
Background: Identifying phenotypes in sepsis patients may enable precision medicine approaches. However, the generalisability of these phenotypes to specific patient populations is unclear. Given that paediatric cancer patients with sepsis have different host response and pathogen profiles and higher mortality rates when compared to non-cancer patients, we determined whether unique, reproducible, and clinically-relevant sepsis phenotypes exist in this specific patient population., Methods: We studied patients with underlying malignancies admitted with sepsis to one of 25 paediatric intensive care units (PICUs) participating in two large, multi-centre, observational cohorts from the European SCOTER study (n = 383 patients; study period between January 1, 2018 and January 1, 2020) and the U.S. Novel Data-Driven Sepsis Phenotypes in Children study (n = 1898 patients; study period between January 1, 2012 and January 1, 2018). We independently used latent class analysis (LCA) in both cohorts to identify phenotypes using demographic, clinical, and laboratory data from the first 24 h of PICU admission. We then tested the association of the phenotypes with clinical outcomes in both cohorts., Findings: LCA identified two distinct phenotypes that were comparable across both cohorts. Phenotype 1 was characterised by lower serum bicarbonate and albumin, markedly increased lactate and hepatic, renal, and coagulation abnormalities when compared to phenotype 2. Patients with phenotype 1 had a higher 90-day mortality (European cohort 29.2% versus 13.4%, U.S. cohort 27.3% versus 11.4%, p < 0.001) and received more vasopressor and renal replacement therapy than patients with phenotype 2. After adjusting for severity of organ dysfunction, haematological cancer, prior stem cell transplantation and age, phenotype 1 was associated with an adjusted OR of death at 90-day of 1.9 (1.04-3.34) in the European cohort and 1.6 (1.2-2.2) in the U.S. cohort., Interpretation: We identified two clinically-relevant sepsis phenotypes in paediatric cancer patients that are reproducible across two international, multicentre cohorts with prognostic implications. These results may guide further research regarding therapeutic approaches for these specific phenotypes., Funding: Part of this study is funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development., Competing Interests: LDJB is supported by the Amsterdam UMC fellowship, Health Holland, ZonMW, Innovative Medicine Initiative, and by the Dutch Lung Foundation (Longfonds) through the Dirkje Postma Award and personal fees from Scailyte, Sobi NL, Impentri, Novartis, AstraZeneca and CLS Behring, outside the submitted work. AM received personal fees from Dräger, outside the submitted work. CMR reports a research grant from the Indiana University Pediatric Critical Care, outside the submitted work. TDB reports funding from U.S. AHRQ (R18 HS029298), outside the submitted work. EVSF repots funding from US NIH, outside the submitted work. SLW reports grants from the US NIH/NICHD (R01HD102396 and R01HD105939) and NIH/National Institute of General Medical Sciences (R21GM146159), and royalties from Up To Date, outside the submitted work. LNS reports grants from the US NIH (R01HD105939 and R21GM146159), and personal fees from Celldom, Saccharo, Allyx, outside the submitted work., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
19. Recommendations for Nutritional Supplementation in Pediatric Oncology: A Compilation of the Facts.
- Author
-
Podpeskar A, Crazzolara R, Kropshofer G, Hetzer B, Rabensteiner E, Meister B, Obexer P, and Salvador C
- Subjects
- Child, Humans, Dietary Supplements, Vitamin D, Micronutrients, Vitamins therapeutic use, Neoplasms complications
- Abstract
Background: As one of the few modifiable risk factors, the importance of dietary patterns for both disease prevention and treatment outcome in pediatric oncology has gained increasing popularity. Malnutrition is associated with lower survival rates, tolerance to treatment, and quality of life. Yet, especially in children with malignancies, nutritional deterioration is common, and pediatric cancer patients often present with inadequate intake of micro- and macronutrients alike. Despite the reported widespread use of dietary supplements, few empirical data provide a basis for clinical recommendations, and evidence for their efficacy is inconsistent. Current literature lacks a systematic approach as to how and which supplements should be recommended for specific patients, types of cancer, or during specific treatments. The aim of this review is to highlight the role of the most frequently used nutrients in pediatric malignant diseases and to give a practical guide based on current scientific evidence., Methods: A comprehensive literature search was conducted on PubMed through April 2023 to select meta-analyses, systematic reviews, observational studies, and individual randomized controlled trials (RCTs) of macro- and micronutrient supplementation in pediatric oncology. The search strategy included the following medical subject headings (MeSH) and keywords: "childhood cancer", "pediatric oncology", "nutritional status", "dietary supplements", "vitamins", "micronutrients", "calcium", "magnesium", "vitamin D", "zinc" "glutamine", "selen", and "omega-3 fatty acids". The reference lists of all relevant articles were screened to include potentially pertinent studies., Results: The present review provides a comprehensive and updated overview of the latest evidence about the role of nutrition and diet in pediatric oncology, also focusing on different nutritional interventions available for the management of the disease. We summarize evidence about the importance of adequate nutrition in childhood cancer and the role of several micronutrients and critically interpret the findings. Possible effects and benefits of supplementation during chemotherapy are discussed, as are strategies for primary and secondary prevention., Conclusions: We here describe the obvious benefits of dietary supplementation for childhood cancer. Further large-scale clinical trials are required to verify the impacts of deficiencies and the possible benefits of supplementation and optimal dosages. (337 words).
- Published
- 2023
- Full Text
- View/download PDF
20. Injuries related to sauna bathing.
- Author
-
Kaiser P, Seeher U, Krasniqi A, Keiler A, Crazzolara R, and Meryk A
- Subjects
- Humans, Male, Female, Retrospective Studies, Dizziness complications, Syncope complications, Steam Bath adverse effects, Burns etiology
- Abstract
Purpose: Awareness of well-being and health issues have contributed to increased popularity of sauna bathing. However, little is known about potential risks and injuries. The aim of this study was to identify the causes for injuries, the affected body regions and to define recommendations for prevention., Methods: A retrospective chart data analysis was conducted among patients treated for an injury related to sauna bathing at the local trauma centre of the Medical University of Innsbruck between January 1, 2005 and December 31, 2021. Patients' demographics, the cause for the injury, the diagnosis, the body region of the trauma and the treatment methods were collected., Results: Two hundred and nine patients with injuries related to sauna bathing (83 female [39.7%] and 126 male [60.3%]) were identified. Fifty-one patients showed more than one injuries leading to a total of 274 diagnosis: contusions/distorsions (113; 41.2%), wounds (79; 28.8%), fractures (42; 15.3%), ligament injuries (17; 6.2%), concussions (15; 5.5%), burns (4; 1.5%) and brain bleeding (3; 1.1%). The most common cause for an injury was a slip/fall (157; 57.5%) followed by dizziness/syncope (82; 30.0%). Interestingly, head and face injuries were mostly caused by dizziness/syncope, whereas slip/fall was the leading cause for injuries of foot, hand, forearm and wrist. Nine patients(4.3%) needed surgical treatment mainly due to fractures. Eight patients got injured by wood splinters. One patient sustained grade IIB-III burns lying unconscious with an alcohol intoxication of 3.6‰ in the sauna., Conclusion: The main causes for injuries during sauna bathing were slip/falls and dizziness/syncopes. The latter one might be prevented by improved of the personal behaviour (e.g. drink enough water before and after each sauna bathing), whereas slip/falls might be prevented by the revision of safety regulations, particularly the obligation to wear slip resistant slippers. Thus, everyone himself as well as the operators can contribute to reduce injuries related sauna bathing., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
21. Can virtual care reduce treatment burden in pediatric leukemia? A retrospective cost analysis.
- Author
-
Dreher J, Meryk A, Riedl D, Kropshofer G, Hetzer B, Neururer S, Pfeifer B, Schneeberger-Carta V, Holzner B, and Crazzolara R
- Abstract
We conducted a retrospective analysis to determine the potential reduction in treatment burden through the expansion of virtual care among children with leukemia (n = 152). Patients living in urban areas traveled median distances of 1555 km compared with 7536 km for patients living in rural areas (p < .05). For the latter group, a median reduction in travel distance of 3560 km (interquartile range [IQR], 2136-5787 km), travel time of 51 h (IQR, 26-78 h), and CO
2 emissions of 623 kg (IQR, 374-1013 kg) was estimated, if every second visit was replaced by video consultations., (© 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.)- Published
- 2023
- Full Text
- View/download PDF
22. Disagreement between mothers' and fathers' rating of health-related quality of life in children with cancer.
- Author
-
Meryk A, Kropshofer G, Hetzer B, Riedl D, Lehmann J, Rumpold G, Haid A, Schneeberger-Carta V, Salvador C, Rabensteiner E, Rothmund MS, Holzner B, and Crazzolara R
- Subjects
- Female, Humans, Child, Male, Quality of Life psychology, Cohort Studies, Parents, Surveys and Questionnaires, Fathers, Mothers, Neoplasms
- Abstract
Purpose: Serial assessment of health condition based on self-report made by children and their proxies has consistently shown a lack of congruence. The study explored the discrepancies between mother's, father's, and children's reports on health-related quality of life (HRQOL) during the first two months of pediatric cancer treatment., Methods: In this cohort study, children and parents completed the generic and cancer-specific Pediatric Quality-of-Life Inventory (PedsQL) questionnaires at initial diagnosis and in the subsequent months. Evaluation of discrepancies included intraclass correlations between mother-child and father-child dyads at different domain levels., Results: Thirty-six children with a diagnosis of cancer between May 2020 and November 2021 and their parents were included in this study. At diagnosis, mother-child dyads showed better agreement on more domains of the PedsQL Generic Core Scale than father-child dyads; moderate agreement persisted for both parents at subsequent time points on the physical domain. The disease-specific PedsQL Cancer Module revealed moderate and better agreement for mother-child dyads during active cancer therapy. In particular, agreement of mother-child dyads was pronounced for domains such as worry (0.77 [95% CI 0.52-0.89, P < 0.001]), whereas fathers tended to overestimate the child's symptom burden for most of the remaining domains of the PedsQL Cancer Module., Conclusion: This cohort study shows that both parent proxy reports can provide valid information on child's HRQOL, but that fathers tend to overestimate, particularly for non-observable domains. Proxy reports derived from mothers more closely agreed with children's HRQOL and might be more weighted, if there is uncertainty between parents., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
23. Immature platelet fraction predicts early marrow recovery after severe chemotherapy associated neutropenia.
- Author
-
Salvador C, Meryk A, Hetzer B, Bargehr C, Kropshofer G, Meister B, Anliker M, and Crazzolara R
- Subjects
- Child, Humans, Bone Marrow, Retrospective Studies, Blood Platelets, C-Reactive Protein, Vegetables, Neuroectodermal Tumors, Primitive, Peripheral, Sarcoma, Ewing drug therapy, Febrile Neutropenia
- Abstract
Febrile neutropenia secondary to chemotherapy is one of the most critical complications in cancer treatment. The aim of this study was to determine if an increase in the percentage of immature platelet fraction (IPF%) might predict early neutrophil recovery following cytostatic-dependent aplasia. A retrospective cohort study compared serial complete blood counts and the level of C-reactive protein (CRP) following induction chemotherapy for Ewing sarcoma and Non-Ewing sarcoma patients. The measurements were taken on a Sysmex XE-2100 instrument. A total of 287 paired samples from 28 children after the first cycle of chemotherapy were analyzed to test if an increase in the IPF% anticipated the CRP peak and recovery of neutrophil count. The chemotherapy associated nadir of neutrophils, reticulocytes and platelets was reached at 9.7 ± 1.5, 11.0 ± 1.7 and 11.9 ± 0.9 days (mean ± SD) respectively, in Ewing sarcoma patients. Still in severe neutropenia, IPF% was the first parameter that significantly increased and anticipated the CRP peak (11.9 ± 1.6 days, mean ± SD). The IPF% continuously increased (maximum = 6.56% ± 2.8%, mean ± SD) and peaked at 12.2 ± 1.4 days (mean ± SD) after commencement of chemotherapy. Compared to neutrophil recovery (14.6 ± 1.4 days, mean ± SD), the IPF% peak was anticipated by 2.4 days (p = 0.0085). Although variably treated, in non-Ewing sarcoma patients the effect was similar and the IPF% peak anticipated neutrophil recovery by 6.8 ± 4.7 days (p < 0.01). IPF% increased significantly at > 48 h before neutrophil recovery in patients treated with chemotherapy. IPF% is an inexpensive parameter and may be valuable in the management of febrile neutropenia., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
24. A critical evaluation of the content validity of patient-reported outcome measures assessing health-related quality of life in children with cancer: a systematic review.
- Author
-
Rothmund M, Meryk A, Rumpold G, Crazzolara R, Sodergren S, Darlington AS, and Riedl D
- Subjects
- Humans, Child, Patient Reported Outcome Measures, Surveys and Questionnaires, Qualitative Research, Quality of Life psychology, Neoplasms therapy
- Abstract
Background: With increasing survival rates in pediatric oncology, the need to monitor health-related quality of life (HRQOL) is becoming even more important. However, available patient-reported outcome measures (PROMs) have been criticized. This review aims to systematically evaluate the content validity of PROMs for HRQOL in children with cancer., Methods: In December 2021, a systematic literature search was conducted in PubMed. PROMs were included if they were used to assess HRQOL in children with cancer and had a lower age-limit between 8 and 12 years and an upper age-limit below 21 years. The COSMIN methodology for assessing the content validity of PROMs was applied to grade evidence for relevance, comprehensiveness, and comprehensibility based on quality ratings of development studies (i.e., studies related to concept elicitation and cognitive interviews for newly developed questionnaires) and content validity studies (i.e., qualitative studies in new samples to evaluate the content validity of existing questionnaires)., Results: Twelve PROMs were included. Due to insufficient patient involvement and/or poor reporting, the quality of most development studies was rated 'doubtful' or 'inadequate'. Few content validity studies were available, and these were mostly 'inadequate'. Following the COSMIN methodology, evidence for content validity was 'low' or 'very low' for almost all PROMs. Only the PROMIS Pediatric Profile had 'moderate' evidence. In general, the results indicated that the PROMs covered relevant issues, while results for comprehensiveness and comprehensibility were partly inconsistent or insufficient., Discussion: Following the COSMIN methodology, there is scarce evidence for the content validity of available PROMs for HRQOL in children with cancer. Most instruments were developed before the publication of milestone guidelines and therefore were not able to fulfill all requirements. Efforts are needed to catch up with methodological progress made during the last decade. Further research should adhere to recent guidelines to develop new instruments and to strengthen the evidence for existing PROMs., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
25. What We Learn from Surveillance of Microbial Colonization in Recipients of Pediatric Hematopoietic Stem Cell Transplantation.
- Author
-
Kropshofer G, Hetzer B, Knoll M, Meryk A, Salvador C, Rabensteiner E, and Crazzolara R
- Abstract
Infections in hematopoietic stem cell transplant (HSCT) remain one of the major causes for morbidity and mortality, and it is still unclear whether knowledge of microbial colonization is important. In this single-center study, we collected weekly surveillance cultures in pediatric recipients of allogenic HSCT from five different body regions and tested for bacteria and fungi. Between January 2010 and December 2021, we collected 1095 swabs from 57 recipients of allogeneic HSCTs (median age: 7.5 years, IQR 1−3: 2.5−11.9). The incidence of positive microbiological cultures (n = 220; 20.1%) differed according to the anatomic localization (p < 0.001) and was most frequent in the anal region (n = 98), followed by the genital, pharyngeal and nasal regions (n = 55, n = 37 and n = 16, respectively). Gram-positive bacteria (70.4%) were the most commonly isolated organisms, followed by fungi (18.6%), Gram-negative (5.5%), non-fermenting bacteria (1.4%), and other flora (4.1%). No association with increased risk of infection (n = 32) or septicemia (n = 7) was noted. Over time, we did not observe any increase in bacterial resistance. We conclude that there is no benefit to surveillance of microbial colonization by culture-based techniques in pediatric HSCT. Sequencing methods might enhance the detection of pathogens, but its role is still to be defined.
- Published
- 2022
- Full Text
- View/download PDF
26. Organizational characteristics of European pediatric onco-critical care: An international cross-sectional survey.
- Author
-
Nielsen JSA, Agbeko R, Bate J, Jordan I, Dohna-Schwake C, Potratz J, Moscatelli A, Bottari G, Pappachan J, Witt V, Crazzolara R, Amigoni A, Mizia-Malarz A, Sánchez Martín M, Willems J, van den Heuvel-Eibrink MM, Schlapbach LJ, and Wösten-van Asperen RM
- Abstract
Background: Intensified treatment protocols have improved survival of pediatric oncology patients. However, these treatment protocols are associated with increased treatment-related morbidity requiring admission to pediatric intensive care unit (PICU). We aimed to describe the organizational characteristics and processes of care for this patient group across PICUs in Europe., Methods: A web-based survey was sent to PICU directors or representative physicians between February and June 2021., Results: Responses were obtained from 77 PICUs of 12 European countries. Organizational characteristics were similar across the different countries of Europe. The median number of PICU beds was 12 (IQR 8-16). The majority of the PICUs was staffed by pediatric intensivists and had a 24/7 intensivist coverage. Most PICUs had a nurse-to-patient ratio of 1:1 or 1:2. The median numbers of yearly planned and unplanned PICU admissions of pediatric cancer patients were 20 (IQR 10-45) and 10 (IQR 10-30, respectively. Oncology specific practices within PICU were less common in participating centres. This included implementation of oncology protocols in PICU (30%), daily rounds of PICU physicians on the wards (13%), joint mortality and morbidity meetings or complex patients' discussions (30% and 40%, respectively) and participation of parents during clinical rounds (40%)., Conclusion: Our survey provides an overview on the delivery of critical care for oncology patients in PICU across European countries. Multidisciplinary care for these vulnerable and challenging patients remains complex and challenging. Future studies need to determine the effects of differences in PICU organization and processes of care on patients' outcome., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2022 Nielsen, Agbeko, Bate, Jordan, Dohna-Schwake, Potratz, Moscatelli, Bottari, Pappachan, Witt, Crazzolara, Amigoni, Mizia-Malarz, Sánchez Martín, Willems, van den Heuvel-Eibrink, Schlapbach and Wösten-van Asperen.)
- Published
- 2022
- Full Text
- View/download PDF
27. Supportive methods for childhood acute lymphoblastic leukemia then and now: A compilation for clinical practice.
- Author
-
Podpeskar A, Crazzolara R, Kropshofer G, Obexer P, Rabensteiner E, Michel M, and Salvador C
- Abstract
Survival of childhood acute lymphoblastic leukemia has significantly improved over the past decades. In the early years of chemotherapeutic development, improvement in survival rates could be attained only by increasing the cytostatic dose, also by modulation of the frequency and combination of chemotherapeutic agents associated with severe short- and long-time side-effects and toxicity in a developing child's organism. Years later, new treatment options have yielded promising results through targeted immune and molecular drugs, especially in relapsed and refractory leukemia, and are continuously added to conventional therapy or even replace first-line treatment. Compared to conventional strategies, these new therapies have different side-effects, requiring special supportive measures. Supportive treatment includes the prevention of serious acute and sometimes life-threatening events as well as managing therapy-related long-term side-effects and preemptive treatment of complications and is thus mandatory for successful oncological therapy. Inadequate supportive therapy is still one of the main causes of treatment failure, mortality, poor quality of life, and unsatisfactory long-term outcome in children with acute lymphoblastic leukemia. But nowadays it is a challenge to find a way through the flood of supportive recommendations and guidelines that are available in the literature. Furthermore, the development of new therapies for childhood leukemia has changed the range of supportive methods and must be observed in addition to conventional recommendations. This review aims to provide a clear and recent compilation of the most important supportive methods in the field of childhood leukemia, based on conventional regimes as well as the most promising new therapeutic approaches to date., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Podpeskar, Crazzolara, Kropshofer, Obexer, Rabensteiner, Michel and Salvador.)
- Published
- 2022
- Full Text
- View/download PDF
28. An R307H substitution in GATA1 that prevents Ser310 phosphorylation causes severe fetal anemia.
- Author
-
Hetzer B, Meryk A, Kropshofer G, Bargehr C, Jimenez-Heredia R, Boztug K, Mühlegger BE, Dworzak M, Gruber T, and Crazzolara R
- Subjects
- GATA1 Transcription Factor genetics, Humans, Phosphorylation, Anemia, Mutation, Missense
- Published
- 2022
- Full Text
- View/download PDF
29. Mortality of Hemato-Oncologic Patients Admitted to a Pediatric Intensive Care Unit: A Single-Center Experience.
- Author
-
Pechlaner A, Kropshofer G, Crazzolara R, Hetzer B, Pechlaner R, and Cortina G
- Abstract
Introduction: Mortality in children with hemato-oncologic disease admitted to a pediatric intensive care unit (PICU) is higher compared to the general population. The reasons for this fact remain unexplored. The aim of this study was to assess outcomes and trends in hemato-oncologic patients admitted to a PICU, with analytical emphasis on emergency admissions., Methods: Patients with a hemato-oncologic diagnosis admitted to a tertiary care university hospital PICU between 1 January 2009 and 31 December 2019 were retrospectively analyzed. Additionally, patient mortality 6 months after PICU admission and follow-up mortality until 31 December 2020 were recorded., Measurements and Main Results: We reviewed a total of 701 PICU admissions of 338 children with hemato-oncologic disease, of which 28.5% were emergency admissions with 200 admissions of 122 patients. Of these, 22 patients died, representing a patient mortality of 18.0% and an admission mortality of 11.0% in this group. Follow-up patient mortality was 25.4% in emergency-admitted children. Multivariable analysis revealed severe neutropenia at admission and invasive mechanical ventilation (IMV) as independent risk factors for PICU death ( p = 0.029 and p = 0.002). The total number of PICU admissions of hemato-oncologic patients rose notably over time, from 44 in 2009 to 125 in 2019., Conclusion: Although a high proportion of emergency PICU admissions of hemato-oncologic patients required intensive organ support, mortality seemed to be lower than previously reported. Moreover, in this study, total PICU admissions of the respective children rose notably over time., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Pechlaner, Kropshofer, Crazzolara, Hetzer, Pechlaner and Cortina.)
- Published
- 2022
- Full Text
- View/download PDF
30. Use of Daily Patient-Reported Outcome Measurements in Pediatric Cancer Care.
- Author
-
Meryk A, Kropshofer G, Hetzer B, Riedl D, Lehmann J, Rumpold G, Haid A, Schneeberger-Carta V, Holzner B, and Crazzolara R
- Subjects
- Adult, Child, Cohort Studies, Female, Humans, Male, Nausea epidemiology, Nausea etiology, Pain, Patient Reported Outcome Measures, Neoplasms therapy
- Abstract
Importance: Patient-reported outcome measurements (PROMs) are emerging as an important component of adult cancer care, but little has been done with regard to PROMs for pediatric cancer care., Objectives: To identify pediatric patients with cancer who are at risk of severe adverse effects of treatment and provide individualized supportive care using PROMs., Design, Setting, and Participants: This single-center cohort study with PROMs implemented in daily clinical routine was conducted from May 1, 2020, to November 15, 2021, among pediatric patients with a cancer diagnosis or their proxies. Inclusion criteria were treatment with chemotherapy and at least 30 days of active participation. Patients were followed up until completion of therapy or through ongoing therapy until November 15, 2021; data were analyzed from November 15, 2021, through January 31, 2022., Exposures: Cancer treatment, including chemotherapy, surgery, and radiotherapy., Main Outcomes and Measures: The primary outcome was occurrence and severity of ubiquitous complications of cancer treatment, such as nausea, appetite loss, pain, sleep disturbance, and deterioration of physical functioning. The secondary outcome was the identification of early and appropriate clinical interventions based on detection of cancer-related symptoms via PROMs., Results: A total of 4410 daily PROMs from 7082 therapy days for 40 children (35 children aged 5-18 years and 5 proxies for children aged 1-4 years) (median age, 9.1 [IQR, 6.3-12.2] years; 26 [65.0%] male) were analyzed during a median follow-up of 145.5 (IQR, 103.8-244.5) days. All participants were White. The overall median completion rate was 60.1% (IQR, 37.9%-81.0%); this rate was slightly lower during home care vs inpatient stay (57.5% [IQR, 30.7%-85.9%] vs 65.0% [IQR, 49.6%-92.5%], respectively; P = .01), with a decreasing trend over time (65.6% [IQR, 51.6%-85.9%] for the first 90 days vs 42.9% [IQR, 29.3%-82.3%] for beyond 90 days; P < .001). Severe symptoms were reported on 657 days (14.9%); most symptoms were associated with physical functioning, followed by pain, sleep disturbance, and nausea and appetite loss. In total, 321 adverse events (AEs) and cases of health deterioration were documented, and PROMs were completed for 251 (78.2%) of these events. Across all AEs, self-reported pain was the most useful marker, particularly when analyzed on the day before onset, and was associated with an odds ratio of 3.65 (95% CI, 1.54-8.62; P = .005) for the presence of mucositis., Conclusions and Relevance: The findings of this cohort study suggest that PROMs reflect daily symptoms in pediatric patients with cancer and assist in clinical management and intervention for AEs.
- Published
- 2022
- Full Text
- View/download PDF
31. Indications and Limitations of Sirolimus in the Treatment of Vascular Anomalies-Insights From a Retrospective Case Series.
- Author
-
Karastaneva A, Gasparella P, Tschauner S, Crazzolara R, Kropshofer G, Modl M, Pfleger A, Burmas A, Pocivalnik M, Ulreich R, Zenz W, Schwinger W, Beqo BP, Urban C, Haxhija EQ, Lackner H, and Benesch M
- Abstract
Background: Despite recent developments, the role of sirolimus in the heterogeneous spectrum of vascular anomalies is yet to be defined, in terms of indication, dosage, and therapy duration, recognizing both its potential and limitations., Methods: We retrospectively analyzed 16 children with vascular anomalies treated with sirolimus in two pediatric centers between 2014 and 2020 [male: n = 7, the median age at diagnosis: 4.6 months (range, 0-281.4)]. In addition, repetitive volumetric analyses of the vascular anomalies were performed when possible (11 cases)., Results: Ten patients were diagnosed with vascular malformations and 6 with vascular tumors. The mean therapy duration was 27.2 months (range, 3.5-65). The mean sirolimus level was 8.52 ng/ml (range, 5.38-12.88). All patients except one with central conducting lymphatic anomaly responded to sirolimus, with the most noticeable volume reduction in the first 4-6 months. Additional administration of vincristine was needed in five patients with kaposiform hemangioendothelioma and yielded a response, even in cases, refractory to sirolimus monotherapy. As a single agent, sirolimus led to impressive improvement in a patient with another vascular tumor-advanced epithelioid hemangioendothelioma. Complicated vascular malformations required long-term sirolimus therapy. Side effects of sirolimus included mucositis and laboratory abnormalities. No major infectious episodes were recorded. An infant with COVID-19, diagnosed while on sirolimus therapy, presented with a mild course., Conclusion: In the current series, we reported limitations of sirolimus as monotherapy, addressing the need to redefine its indications, and explore combination regimens and multimodal treatment strategies. Tools for objective evaluation of response trends over time could serve as a basis for the establishment of future therapeutic algorithms., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Karastaneva, Gasparella, Tschauner, Crazzolara, Kropshofer, Modl, Pfleger, Burmas, Pocivalnik, Ulreich, Zenz, Schwinger, Beqo, Urban, Haxhija, Lackner and Benesch.)
- Published
- 2022
- Full Text
- View/download PDF
32. New Therapeutic Approach in an Infant With Systemic Myofibromatosis and Intestinal Hemorrhage.
- Author
-
Salvador C, Entenmann A, Crazzolara R, and Kropshofer G
- Subjects
- Child, Dasatinib therapeutic use, Humans, Infant, Methotrexate therapeutic use, Sirolimus therapeutic use, Vinblastine therapeutic use, Myofibromatosis drug therapy, Myofibromatosis pathology
- Abstract
We report the case of an infant with multicentric myofibromatosis affecting the gastric and intestinal mucosa, leading to continuous intestinal hemorrhage and iron deficiency. Conventional vinblastine and methotrexate combination treatment was administered for 4 months, but persistent intestinal blood loss required repeated blood transfusions. Because of insufficient tumor response to treatment, we opted for the experimental combination of rapamycin and dasatinib. Six weeks after the start of this therapy, hemoglobin levels stabilized without transfusions, and no fecal blood loss was detected. In addition, a follow-up magnetic resonance imaging excluded tumor progression. We here show the effectiveness of an experimental therapy with rapamycin and dasatinib in a child with multicentric myofibromatosis after the failure of conventional therapy with vinblastine and methotrexate., Competing Interests: The authors declare no conflict of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
33. Sepsis in Pediatric Cancer: Does Gender Matter? A 20-Year Retrospective Study.
- Author
-
Meryk A, Kropshofer G, Bargehr C, Knoll M, Hetzer B, Lass-Flörl C, and Crazzolara R
- Abstract
Introduction: Gender plays an active role in the incidence and outcome of many infectious and malignant diseases. However, there is still no study examining sex differences for developing bloodstream infections (BSIs) in pediatric patients with cancer. We sought to identify potential gender-specific risk factors for BSIs., Methods: Data were retrospectively analyzed from 621 pediatric patients treated for childhood cancer in a tertiary single center between 1 January 2000 and 31 June 2018. After central venous access device (CVAD) placement, patients were followed up until CVAD was removed or at the most for 1 year. We calculated the gender-specific prevalence for BSIs and compared the causative bacterial strains., Results: Of 621 pediatric patients with cancer (283 girls [45.6%] and 338 boys [54.4%]), 110 patients (41 girls [37.3%] and 69 boys [62.7%]) were identified with a total of 134 BSIs. Girls and boys had a similar incidence for BSI (13%) within the first 3 months of therapy, after which the risk for BSI increased significantly for boys (34% versus 21%, boys versus girls, P = 0.025). Moreover, BSI with gram-positive bacteria affected boys nearly twice as often as girls (29.8% versus 56.5%, girls versus boys)., Conclusions: Future clinical awareness of hygiene-related BSIs in boys could be helpful in identifying areas for improvement., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
34. Role of extracorporeal membrane oxygenation in pediatric cancer patients: a systematic review and meta-analysis of observational studies.
- Author
-
Slooff V, Hoogendoorn R, Nielsen JSA, Pappachan J, Amigoni A, Caramelli F, Aziz O, Wildschut E, Verbruggen S, Crazzolara R, Dohna-Schwake C, Potratz J, Willems J, Llevadias J, Moscatelli A, Montaguti A, Bottari G, Di Nardo M, Schlapbach L, and Wösten-van Asperen R
- Abstract
Background: The use of extracorporeal membrane oxygenation (ECMO) in pediatric patients with underlying malignancies remains controversial. However, in an era in which the survival rates for children with malignancies have increased significantly and several recent reports have demonstrated effective ECMO use in children with cancer, we aimed to estimate the outcome and complications of ECMO treatment in these children., Methods: We searched MEDLINE, Embase and CINAHL databases for studies on the use ECMO in pediatric patients with an underlying malignancy from inception to September 2020. This review was conducted in adherence to Preferred Reporting Items for Systematic Review and Meta-Analysis statement. Study eligibility was independently assessed by two authors and disagreements resolved by a third author. Included studies were evaluated for quality using the Newcastle-Ottawa Scale (NOS). Random effects meta-analyses (DerSimonian and Laird) were performed. The primary outcomes were mortality during ECMO or hospital mortality., Results: Thirteen retrospective, observational cohort studies were included, most of moderate quality (625 patients). The commonest indication for ECMO was severe respiratory failure (92%). Pooled mortality during ECMO was 55% (95% confidence interval [CI], 47-63%) and pooled hospital mortality was 60% (95% CI 54-67%). Although heterogeneity among the included studies was low, confidence intervals were large. In addition, the majority of the data were derived from registries with overlapping patients which were excluded for the meta-analyses to prevent resampling of the same participants across the included studies. Finally, there was a lack of consistent complications reporting among the studies., Conclusion: Significantly higher mortalities than in general PICU patients was reported with the use of ECMO in children with malignancies. Although these results need to be interpreted with caution due to the lack of granular data, they suggest that ECMO appears to represents a viable rescue option for selected patients with underlying malignancies. There is an urgent need for additional data to define patients for whom ECMO may provide benefit or harm., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
35. Bridging the gap in outpatient care: Can a daily patient-reported outcome measure help?
- Author
-
Meryk A, Kropshofer G, Hetzer B, Riedl D, Lehmann J, Rumpold G, Haid A, Holzner B, and Crazzolara R
- Subjects
- Burkitt Lymphoma psychology, Child, Fatigue chemically induced, Humans, Male, Nausea chemically induced, Stomatitis chemically induced, Antineoplastic Agents adverse effects, Burkitt Lymphoma drug therapy, Patient Reported Outcome Measures
- Abstract
Background: Childhood patients have high risks for developing debilitating somatic and mental health side-effects as a consequence of the many different approaches employed in treating their cancer. Early recognition and close monitoring of clinical and psychological problems are essential in planning appropriate interventions and preventing further deterioration., Case: ePROtect was established as an easy-to-use application for daily self-reporting of symptoms during cancer therapy. ePROtect includes six to eight questions pertaining to seven common symptoms: appetite loss, fatigue, nausea, pain, physical functioning, cognitive impairments and sleep quality. The case of a child diagnosed with Burkitt leukemia developing chemotherapy-induced oral mucositis in home care is presented to show the therapeutic impact of early symptom detection with a daily web-based tool., Conclusion: This case highlights how electronic patient-reported outcome measures (PROM) can directly facilitate patient care in real time and might be incorporated in future clinical routine., (© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
36. Implementation of daily patient-reported outcome measurements to support children with cancer.
- Author
-
Meryk A, Kropshofer G, Hetzer B, Riedl D, Lehmann J, Rumpold G, Haid A, Holzner B, and Crazzolara R
- Subjects
- Adolescent, Child, Child, Preschool, Delivery of Health Care, Humans, Neoplasms therapy, Patient Reported Outcome Measures
- Abstract
Background: Several stakeholders, including patients and health care providers, suggest symptom self-reporting measurements for a more patient-directed cancer control approach. However, services tailored to measure daily reporting and implementing it in clinical care are lacking. This study aimed to evaluate the feasibility and value of daily patient-reported outcome measures (PROMs) by children receiving chemotherapy for cancer., Methods: Health status was recorded daily with a web-based child-friendly patient portal (ePROtect). Following aspects of feasibility and usability were assessed: (a) the completion rate and time, (b) user feedback on usability and satisfaction, and (c) the performed interventions if moderate to severe symptom deterioration was noted., Results: Twelve children (median age: 7.2 years) were included. A total number of 891 daily reports were collected during the study period; the median percentage of ePROtect completion days was 85.3% (interquartile range [IQR] 64.2-100.0) and 55.9% (IQR 51.9-76.9) for inpatient and outpatient stay, respectively. Mean time to complete the questionnaire was 47.6 seconds. Severe symptoms were reported in 14.7% of measurement time points, which led to prompt health care interventions in 57 cases, including extension of supportive care (n = 37) and pre-emptive inpatient admissions (n = 5). Over 80% of the patients (10/12) and their proxies (16/18) provided feedback with high rating for satisfaction (>90%) and usefulness (>80%) of ePROtect., Conclusion: Our study shows that daily symptom monitoring is feasible for all children with newly diagnosed cancer aged 5-18 years. Monitoring offers the opportunity to identify symptoms early and trigger appropriate clinical action., (© 2021 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
37. Hyponatremia During Induction Therapy in Distinct Pediatric Oncological Cohorts: A Retrospective Study.
- Author
-
Salvador C, Salvador R, Willeit P, Kuntner C, Haid A, Müller T, Kropshofer G, and Crazzolara R
- Abstract
Background: Hyponatremia is a well-known adverse event of repeated therapy with vincristine in oncological patients. However, to date, data in pediatric patients with malignant diseases other than acute lymphoblastic leukemia (ALL) are sparse or lacking., Materials and Methods: A retrospective study of 98 pediatric patients was conducted to analyze the incidence of hyponatremia in a Caucasian cohort of newly diagnosed ALL. For comparison, we further examined five other pediatric oncological cohorts (Hodgkin's disease, Ewing sarcoma, Wilms tumor, benign glioma of the CNS, Langerhans cell histiocytosis) that receive alkaloids in their induction regimes., Results: We found a high incidence of hyponatremia (14.7%) in our ALL cohort with a trend toward male patients of elementary school age. None of the affected patients showed neurological symptoms. By comparison, patients from other malignancy groups did not show significant hyponatremia, regardless of their comparable therapy with alkaloids. We here show a noticeable coincidence of hyponatremia and hypertriglyceridemia in ALL patients, indicating a possible role of L-asparaginase-related hypertriglyceridemia in the development of severe hyponatremia in such patients., Conclusion: We report a higher incidence of hyponatremia following vincristine therapy in Caucasian children with ALL than published before. This hyponatremia could not be demonstrated in other oncologic cohorts treated with alkaloids. L-Asparaginase-induced hypertriglyceridemia may play a role in the certainly multifactorial development of hyponatremia in childhood leukemia., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Salvador, Salvador, Willeit, Kuntner, Haid, Müller, Kropshofer and Crazzolara.)
- Published
- 2021
- Full Text
- View/download PDF
38. Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.
- Author
-
Füreder A, Kropshofer G, Benesch M, Dworzak M, Greil S, Huber WD, Hubmann H, Lawitschka A, Mann G, Michel-Behnke I, Müller-Sacherer T, Pichler H, Simonitsch-Klupp I, Schwinger W, Szepfalusi Z, Crazzolara R, and Attarbaschi A
- Subjects
- Adolescent, Adult, Austria epidemiology, Child, Child, Preschool, Disease Management, Female, Follow-Up Studies, Hematologic Neoplasms pathology, Humans, Infant, Infant, Newborn, Lymphoproliferative Disorders epidemiology, Lymphoproliferative Disorders etiology, Lymphoproliferative Disorders pathology, Male, Prognosis, Retrospective Studies, Survival Rate, Transplantation, Homologous, Young Adult, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation adverse effects, Lymphoproliferative Disorders mortality, Organ Transplantation adverse effects
- Abstract
Background: Management of pediatric post-transplantation lymphoproliferative disorder (PTLD) after hematopoietic stem cell (HSCT) and solid organ transplantation (SOT) is challenging., Aim: This study of 34 PTLD patients up to 19-years old diagnosed in Austria from 2000 to 2018 aimed at assessing initial characteristics, therapy, response, and outcome as well as prognostic markers of this rare pediatric disease., Methods and Results: A retrospective data analysis was performed. Types of allografts were kidney (n = 12), liver (n = 7), heart (n = 5), hematopoietic stem cells (n = 4), lungs (n = 2), multi-visceral (n = 2), small intestine (n = 1), and vessels (n = 1). Eighteen/34 were classified as monomorphic PTLD, with DLBCL accounting for 15 cases. Polymorphic disease occurred in nine, and non-destructive lesions in six cases. One patient had a non-classifiable PTLD. Thirteen/34 patients are surviving event-free in first remission (non-destructive, n = 4/6; polymorphic, n = 4/9; monomorphic, n = 6/18). Fourteen/34 patients lacked complete response to first-line therapy, of whom seven died. Four/34 patients relapsed, of whom two died. In 3/34 patients, death occurred as a first event. The 5-year overall and event-free survival rates were 64% ± 9% and 35% ± 9% for the whole cohort. Among all parameters analyzed, only malignant disease as the indication for transplantation had a significantly poor influence on survival., Conclusions: This study shows PTLD still to be a major cause of mortality following SOT or HSCT in children. A continued understanding of the molecular biology of the disease shall allow to decrease treatment intensity for lower risk patients and to identify patients who may benefit from newer therapy approaches to improve outcome and decrease morbidity., (© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
39. Rare use of patient-reported outcomes in childhood cancer clinical trials - a systematic review of clinical trial registries.
- Author
-
Riedl D, Rothmund M, Darlington AS, Sodergren S, Crazzolara R, and de Rojas T
- Subjects
- Antineoplastic Agents adverse effects, Child, Clinical Trials as Topic standards, Humans, Medical Oncology standards, Medical Oncology statistics & numerical data, Neoplasms diagnosis, Neoplasms psychology, Patient-Centered Care standards, Quality of Life, Research Design standards, Research Design statistics & numerical data, Antineoplastic Agents administration & dosage, Clinical Trials as Topic statistics & numerical data, Neoplasms drug therapy, Patient Reported Outcome Measures, Registries statistics & numerical data
- Abstract
Background: Patient-reported outcomes (PROs) are the gold standard to assess the patients' subjective health status. While both the Food and Drug Administration and European Medicines Agency recommend the use of PROs as end-points in paediatric clinical trials to support claims for medical product labelling, it is not known how often PROs are actually used. The aim of this study was to assess the usage of PRO instruments in childhood cancer clinical trials investigating anti-cancer medication., Methods: In June 2020 ClinicalTrials and EudraCT were systematically searched for all trials including children and adolescents (≤21 years) with cancer registered between 2007 and 2020. The use of PRO measures and trials characteristics were analysed. To investigate which trial characteristics are associated with the use of PROs, a binary logistic regression was calculated., Results: Of 4789 identified trials, 711 were included. The most frequent reason for exclusion was age limitation (age >21 years). Of all included trials, only 8.2% used PROs as end-points; .6% as the primary end-point. The most commonly used questionnaire was the PedsQL™ (32.8%), followed by the Patient-Reported Outcomes Measurement Information System scales (12.1%). No association was observed between the use of PROs and trial region, number of centres, trial phase, time period or intervention type (all p > .05). The use of PROs did not substantially increase over time. Only 20.3% of the closed studies had published their results., Conclusion: Despite recommendations of regulatory agencies, PRO assessment is extremely rare in paediatric oncology clinical trials. More efforts should be undertaken to facilitate implementation of PRO in paediatric trials to guarantee patient-centred research and treatments., Competing Interests: Conflict of interest statement None declared., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
40. Which Type of Empiric Antibiotic Therapy is Appropriate? A 20-Year Retrospective Study of Bloodstream Infections in Childhood Cancer.
- Author
-
Meryk A, Kropshofer G, Bargehr C, Knoll M, Hetzer B, Lass-Flörl C, and Crazzolara R
- Abstract
Introduction: Sufficient empirical antimicrobial therapy in febrile patients with cancer is challenging, owing to the limited arsenal of available antibiotics in an era of growing resistance. Because of the emergence of gram-negative bacteria resistant to ceftazidime and piperacillin, a combination antibiotic therapy was employed that uses meropenem combined with gentamicin and/or vancomycin if the patient further deteriorates., Methods: A retrospective cohort analysis was performed including all patients with catheter-associated bloodstream infections (BSIs) and treated for childhood cancer in a tertiary single centre between 1 January 2000 and 31 June 2018. We calculated the prevalence and the risk for BSIs and compared the in vitro susceptibility to various antimicrobial agents., Results: Of 653 patients with childhood cancer, 113 patients (17.3%) were identified with a total of 139 BSIs, most of them occurring in patients with leukaemia (n = 90, 64.7%) and were associated with gram-positive bacteria (60.5%). In our cohort, all BSIs with gram-negative bacteria exhibited in vitro susceptibility against meropenem alone without any signs of resistance development. The antibiotic coverage of our meropenem-based combination therapy was also highly effective for gram-positive and non-fermenting bacteria. Thus, BSI-related mortality in all 139 BSI episodes was 1.4%. Clostridium difficile infections (CDIs), as main adverse event of carbapenem usage, occurred in only 16 (2.5%) patients., Conclusion: Our meropenem-based combination therapy showed sufficient empirical antibiotic coverage in the majority of BSIs (96.4%) and did not result in an increased rate of unwanted side effects or development of antibiotic resistance.
- Published
- 2021
- Full Text
- View/download PDF
41. Omega-3 Fatty Acids and Their Role in Pediatric Cancer.
- Author
-
Podpeskar A, Crazzolara R, Kropshofer G, Hetzer B, Meister B, Müller T, and Salvador C
- Subjects
- Cancer Survivors, Child, Cytokines, Databases, Factual, Drug Therapy, Fatty Acids, Omega-6 therapeutic use, Humans, Malnutrition, Neoplasms epidemiology, Nutritional Status, Prevalence, Dietary Supplements, Fatty Acids, Omega-3 therapeutic use, Neoplasms prevention & control
- Abstract
Background: Malnutrition is common in children with cancer and is associated with adverse clinical outcomes. The need for supportive care is becoming ever more evident and the role of nutrition in oncology is still not sufficiently understood. In particular, the consequences of macro- and micronutrient deficiencies require further research. As epidemiological data suggest anti-tumoral properties of omega-3 (n-3) polyunsaturated fatty acids (PUFAs), we reviewed the role of nutrition and n-3 supplementation in pediatric oncology., Methods: A comprehensive literature search was conducted on PubMed through 5 February 2021 to select meta-analyses, systematic reviews, observational studies, and individual randomized controlled trials (RCTs) on macro- and micronutrient supplementation in pediatric oncology. The search strategy included the following medical subject headings (MeSH) and keywords: "childhood cancer", "pediatric oncology", "nutritional status", "malnutrition", and "omega-3-fatty-acids". The reference lists of all relevant articles were screened to include potentially pertinent studies., Results: We summarize evidence about the importance of adequate nutrition in childhood cancer and the role of n-3 PUFAs and critically interpret findings. Possible effects of supplementation on the nutritional status and benefits during chemotherapy are discussed as well as strategies for primary and secondary prevention., Conclusion: We here describe the obvious benefits of omega-3 supplementation in childhood cancer. Further large scale clinical trials are required to verify potential anti-cancer effects of n-3 fatty acids.
- Published
- 2021
- Full Text
- View/download PDF
42. Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94.
- Author
-
Fiedler S, Ambros IM, Glogova E, Benesch M, Urban C, Mayer M, Ebetsberger-Dachs G, Bardi E, Jones N, Gamper A, Meister B, Crazzolara R, Amann G, Dieckmann K, Horcher E, Kerbl R, Brunner-Herglotz B, Ziegler A, Ambros PF, and Ladenstein R
- Abstract
We evaluated long-term outcome and genomic profiles in the Austrian Neuroblastoma Trial A-NB94 which applied a risk-adapted strategy of treatment (RAST) using stage, age and MYCN amplification (MNA) status for stratification. RAST ranged from surgery only to intensity-adjusted chemotherapy, single or multiple courses of high-dose chemotherapy (HDT) followed by autologous stem cell rescue depending on response to induction chemotherapy, and irradiation to the primary tumor site. Segmental chromosomal alterations (SCAs) were investigated retrospectively using multi- and pan-genomic techniques. The A-NB94 trial enrolled 163 patients. Patients with localized disease had an excellent ten-year (10y) event free survival (EFS) and overall survival (OS) of 99 ± 1% and 93 ± 2% whilst it was 80 ± 13% and 90 ± 9% for infants with stage 4S and for infants with stage 4 non-MNA disease both 83 ± 15%. Stage 4 patients either >12 months or ≤12 months but with MNA had a 10y-EFS and OS of 45 ± 8% and 47 ± 8%, respectively. SCAs were present in increasing frequencies according to stage and age: in 29% of localized tumors but in 92% of stage 4 tumors ( p < 0.001), and in 39% of patients ≤ 12 months but in 63% of patients > 12 months ( p < 0.001). RAST successfully reduced chemotherapy exposure in low- and intermediate-risk patients with excellent long-term results while the outcome of high-risk disease met contemporary trials.
- Published
- 2021
- Full Text
- View/download PDF
43. Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia.
- Author
-
Meryk A, Kropshofer G, Hutter J, Fritz J, Salvador C, Lass-Flörl C, and Crazzolara R
- Subjects
- Child, Child, Preschool, Female, Fluconazole administration & dosage, Humans, Male, Retrospective Studies, Risk Factors, Amphotericin B administration & dosage, Aspergillosis etiology, Aspergillosis prevention & control, Aspergillus, Leukemia therapy
- Abstract
Fluconazole is one of the most commonly used drugs for antifungal prophylaxis in childhood leukaemia. However, its interaction with vincristine may induce neuropathy and the emergence of antifungal drug resistance contributes to substantial mortality caused by invasive fungal infections (IFIs). In a retrospective single-centre study, we compared tolerability and outcome of different antifungal prophylaxis strategies in 198 children with acute leukaemia (median age 5·3 years). Until 2010, antifungal prophylaxis with fluconazole was offered to most of the patients and thereafter was replaced by liposomal amphotericin-B (L-AMB) and restricted to high-risk patients only. Vincristine-induced neurotoxicity was significantly reduced under L-AMB, as the percentage of patients with severe constipation decreased (15·4% vs. 3·7%, before vs. after 31 December·2010, P = 0·01) and stool frequency increased by up to 38% in polyene-treated patients (P = 0·005). Before 2011, 10 patients developed confirmed IFIs, most of them were infected with Aspergillus species. After risk adaption in 2011, IFIs were completely prevented (P = 0·007). L-AMB prophylaxis is beneficial in childhood leukaemia patients, as it offers effective antifungal activity with improved tolerability as compared to fluconazole. The potential impact of our risk-adapted antifungal treatment should be included in current prophylaxis guidelines for childhood leukaemia., (© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
44. SARS-CoV-2 infection in a 7-year-old girl with pancytopenia during acute lymphocytic leukemia maintenance therapy.
- Author
-
Bernar B, Kropshofer G, Crazzolara R, Kapelari K, Griesmacher A, Müller T, and Scholl-Bürgi S
- Subjects
- Anti-Bacterial Agents therapeutic use, Antimetabolites, Antineoplastic therapeutic use, Antiviral Agents therapeutic use, Austria, COVID-19 complications, Child, Female, Humans, Mercaptopurine therapeutic use, Methotrexate therapeutic use, Pancytopenia diagnosis, Polymerase Chain Reaction, SARS-CoV-2 isolation & purification, Treatment Outcome, COVID-19 Drug Treatment, COVID-19 diagnosis, Pancytopenia complications, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Published
- 2020
- Full Text
- View/download PDF
45. Cabot rings and other peripheral blood features of Imerslund-Gräsbeck syndrome.
- Author
-
Bargehr C and Crazzolara R
- Subjects
- Child, Preschool, Female, Hemoglobins metabolism, Humans, Anemia, Megaloblastic blood, Anemia, Megaloblastic genetics, Anemia, Megaloblastic pathology, Anemia, Megaloblastic therapy, Blood Cells metabolism, Blood Cells pathology, Blood Transfusion, Homozygote, Malabsorption Syndromes blood, Malabsorption Syndromes genetics, Malabsorption Syndromes pathology, Malabsorption Syndromes therapy, Membrane Proteins genetics, Mutation, Proteinuria blood, Proteinuria genetics, Proteinuria pathology, Proteinuria therapy, Vitamin B 12 administration & dosage, Vitamin B 12 Deficiency blood, Vitamin B 12 Deficiency genetics, Vitamin B 12 Deficiency pathology, Vitamin B 12 Deficiency therapy
- Published
- 2020
- Full Text
- View/download PDF
46. Stereotactic radiofrequency ablation of a variety of liver masses in children.
- Author
-
Hetzer B, Vogel GF, Entenmann A, Heil M, Schullian P, Putzer D, Meister B, Crazzolara R, Kropshofer G, Salvador C, Straub S, Karall D, Niederwanger C, Cortina G, Janecke A, Freund-Unsinn K, Maurer K, Schweigmann G, Oberhuber G, Renz O, Schneeberger S, Müller T, and Bale R
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Humans, Infant, Neoplasm Recurrence, Local surgery, Retrospective Studies, Treatment Outcome, Carcinoma, Hepatocellular surgery, Catheter Ablation, Liver Neoplasms diagnostic imaging, Liver Neoplasms surgery, Radiofrequency Ablation
- Abstract
Background and Aims: Surgical resection is currently the cornerstone of liver tumor treatment in children. In adults radiofrequency ablation (RFA) is an established minimally invasive treatment option for small focal liver tumors. Multiprobe stereotactic RFA (SRFA) with intraoperative image fusion to confirm ablation margins allows treatment for large lesions. We describe our experience with SRFA in children with liver masses., Methods: SRFA was performed in 10 patients with a median age of 14 years (range 0.5-17.0 years) suffering from liver adenoma ( n = 3), hepatocellular carcinoma ( n = 1), hepatoblastoma ( n = 2), myofibroblastic tumor ( n = 1), hepatic metastases of extrahepatic tumors ( n = 2) and infiltrative hepatic cysts associated with alveolar echinococcosis ( n = 1). Overall, 15 lesions with a mean lesion size of 2.6 cm (range 0.7-9.5 cm) were treated in 11 sessions., Results: The technical success rate was 100%, as was the survival rate. No transient adverse effects higher than grade II (Clavien and Dindo) were encountered after interventions. The median hospital stay was 5 d (range 2-33 d). In two patients who subsequently underwent transplant hepatectomy complete ablation was histologically confirmed. Follow-up imaging studies (median 55 months, range 18-129 months) revealed no local or distant recurrence of disease in any patient., Conclusions: SRFA is an effective minimal-invasive treatment option in pediatric patients with liver tumors of different etiologies.
- Published
- 2020
- Full Text
- View/download PDF
47. Refractory hyperkalaemic cardiac arrest - What to do first: Treat the reversible cause or initiate E-CPR?
- Author
-
Klingkowski U, Kropshofer G, Crazzolara R, Schachner T, and Cortina G
- Subjects
- Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Burkitt Lymphoma drug therapy, Child, Preschool, Female, Glucocorticoids administration & dosage, Humans, Rituximab administration & dosage, Time-to-Treatment, Treatment Outcome, Tumor Lysis Syndrome blood, Tumor Lysis Syndrome etiology, Tumor Lysis Syndrome therapy, Ventricular Fibrillation etiology, Ventricular Fibrillation therapy, Advanced Cardiac Life Support methods, Extracorporeal Membrane Oxygenation methods, Glucocorticoids adverse effects, Heart Arrest etiology, Heart Arrest therapy, Hyperkalemia etiology, Hyperkalemia therapy, Renal Dialysis methods, Rituximab adverse effects
- Published
- 2019
- Full Text
- View/download PDF
48. Extracorporeal membrane oxygenation offers long-term survival in childhood leukemia and acute respiratory failure.
- Author
-
Cortina G, Neu N, Kropshofer G, Meister B, Klingkowski U, and Crazzolara R
- Subjects
- Extracorporeal Membrane Oxygenation methods, Humans, Leukemia therapy, Pediatrics methods, Respiratory Distress Syndrome therapy, Survival Analysis, Survivors statistics & numerical data, Extracorporeal Membrane Oxygenation standards, Leukemia complications, Respiratory Distress Syndrome complications
- Published
- 2018
- Full Text
- View/download PDF
49. Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies.
- Author
-
Crazzolara R, Kropshofer G, Steurer M, Sopper S, and Schwinger W
- Subjects
- Hemoglobinopathies pathology, Humans, Transplantation Conditioning methods, Erythroid Precursor Cells cytology, Erythroid Precursor Cells transplantation, Hematopoietic Stem Cell Transplantation methods, Hemoglobinopathies therapy, Transplantation Chimera physiology
- Abstract
The presence of incomplete chimerism is noted in a large proportion of patients following bone marrow transplant for thalassemia major or sickle cell disease. This observation has tremendous implications, as subsequent therapeutic immunomodulation strategies can improve clinical outcome. Conventionally, polymerase chain reaction-based analysis of short tandem repeats is used to identify chimerism in donor-derived blood cells. However, this method is restricted to nucleated cells and cannot distinguish between dissociated single-cell lineages. We applied the analysis of short tandem repeats to flow cytometric-sorted hematopoietic progenitor cells and compared this with the analysis of short tandem repeats obtained from selected burst-forming unit - erythroid colonies, both collected from the bone marrow. With this method we are able to demonstrate the different proliferation and differentiation of donor cells in the erythroid compartment. This technique is eligible to complete current monitoring of chimerism in the stem cell transplant setting and thus may be applied in future clinical studies, stem cell research and design of gene therapy trials.
- Published
- 2017
- Full Text
- View/download PDF
50. Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone.
- Author
-
Abbasi MR, Rifatbegovic F, Brunner C, Mann G, Ziegler A, Pötschger U, Crazzolara R, Ussowicz M, Benesch M, Ebetsberger-Dachs G, Chan GCF, Jones N, Ladenstein R, Ambros IM, and Ambros PF
- Subjects
- Adult, Aged, Aged, 80 and over, Bone Marrow Cells pathology, Child, Preschool, Chromosomes, Human, Pair 19 genetics, Disease-Free Survival, Female, Gene Deletion, Genetic Heterogeneity, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Neoplasms, Second Primary pathology, Neoplastic Cells, Circulating pathology, Neuroblastoma pathology, Polymorphism, Single Nucleotide genetics, Recurrence, X-linked Nuclear Protein genetics, Clonal Evolution genetics, Neoplasm Recurrence, Local genetics, Neoplasms, Second Primary genetics, Neuroblastoma genetics
- Abstract
Purpose: Tumor relapse is the most frequent cause of death in stage 4 neuroblastomas. Since genomic information on the relapse precursor cells could guide targeted therapy, our aim was to find the most appropriate tissue for identifying relapse-seeding clones. Experimental design: We analyzed 10 geographically and temporally separated samples of a single patient by SNP array and validated the data in 154 stage 4 patients. Results: In the case study, aberrations unique to certain tissues and time points were evident besides concordant aberrations shared by all samples. Diagnostic bone marrow-derived disseminated tumor cells (DTCs) as well as the metastatic tumor and DTCs at relapse displayed a 1q deletion, not detected in any of the seven primary tumor samples. In the validation cohort, the frequency of 1q deletion was 17.8%, 10%, and 27.5% in the diagnostic DTCs, diagnostic tumors, and DTCs at relapse, respectively. This aberration was significantly associated with 19q and ATRX deletions. We observed a significant increased likelihood of an adverse event in the presence of 19q deletion in the diagnostic DTCs. Conclusions: Different frequencies of 1q and 19q deletions in the primary tumors as compared with DTCs, their relatively high frequency at relapse, and their effect on event-free survival (19q deletion) indicate the relevance of analyzing diagnostic DTCs. Our data support the hypothesis of a branched clonal evolution and a parallel progression of primary and metastatic tumor cells. Therefore, searching for biomarkers to identify the relapse-seeding clone should involve diagnostic DTCs alongside the tumor tissue. Clin Cancer Res; 23(15); 4224-32. ©2017 AACR ., (©2017 American Association for Cancer Research.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.